Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 2/20 | 0.58 |
| ▸ | LMNA | P02545 | 1/20 | 0.58 |
| ▸ | MEN1 | O00255 | 3/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.55 |
| ▸ | TP53 | P04637 | 2/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.52 |
| ▸ | TSHR | P16473 | 1/20 | 0.51 |
| ▸ | POLB | P06746 | 1/20 | 0.51 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.50 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.50 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.44 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4058268 | 0.90 | POLB (0.59) | CYP3A4LMNAMEN1KMT2ATP53 | |
| SCHEMBL4061022 | 0.89 | TP53 (0.59) | CYP3A4LMNAMEN1KMT2ATP53 | |
| SCHEMBL12679901 | 0.87 | CYP3A4 (0.55) | CYP3A4LMNAMEN1KMT2ATP53 | |
| SCHEMBL1114970 | 0.87 | CYP3A4 (0.55) | CYP3A4LMNAMEN1KMT2ATP53 | |
| SCHEMBL13090981 | 0.87 | ALDH1A1 (0.47) | CYP3A4LMNAMEN1KMT2ATP53 | |
| SCHEMBL7867200 | 0.86 | CYP3A4 (0.61) | CYP3A4LMNAMEN1KMT2ATP53 | |
| SCHEMBL4158674 | 0.85 | TP53 (0.56) | CYP3A4LMNAMEN1KMT2ATP53 | |
| SCHEMBL14229016 | 0.85 | TP53 (0.68) | CYP3A4LMNAMEN1KMT2ATP53 | |
| SCHEMBL1114992 | 0.84 | CYP3A4 (0.52) | CYP3A4LMNAMEN1KMT2ATP53 | |
| SCHEMBL12679867 | 0.84 | CYP3A4 (0.52) | CYP3A4LMNAMEN1KMT2ATP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3046560-A1 | STEM CELL MODULATION II | University of Canberra (AU) | 2016-07-27 | — | — | EP | disclosed |
| WO-2015039187-A1 | STEM CELL MODULATION II | UNIVERSITY OF CANBERRA (AU) | 2015-03-26 | — | — | WO | disclosed |
| US-7550473-B2 | Pyrimidine derivatives useful as inhibitors of PKC-theta | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2009-06-23 | — | — | US | disclosed |
| US-20050124640-A1 | Pyrimidine derivatives useful as inhibitors of PKC-theta | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2005-06-09 | — | — | US | disclosed |
| EP-0782861-B1 | DRUG COMPOUNDING INGREDIENTS COMPRISING N-SUBSTITUTED-O-TOLUIDINE DERIVATIVE AND PERCUTANEOUSLY ABSORBABLE PREPARATION | HISAMITSU PHARMACEUTICAL CO (JP) | 2001-12-12 | — | — | EP | disclosed |
| US-5891920-A | Medicinal adjuvants consisting of N-subsitituted-o-toluidine derivatives, and percutaneously absorbable preparations comprising the adjuvants | HISAMITSU PHARMACEUTICAL CO., INC. (JP) | 1999-04-06 | — | — | US | disclosed |
| EP-0782861-A1 | DRUG COMPOUNDING INGREDIENTS COMPRISING N-SUBSTITUTED-O-TOLUIDINE DERIVATIVE AND PERCUTANEOUSLY ABSORBABLE PREPARATION | Hisamitsu Pharmaceutical Co., Inc. (JP) | 1997-07-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050124640-A1 | Pyrimidine derivatives useful as inhibitors of PKC-theta | PRKCQ, PRKCZ, PRKCH | CYP3A4 2949/4885LMNA 2449/4885MEN1 4069/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.